Expanding early cancer detection with high throughput OCEANA - Ovarian Cancer Exosome Analysis with Nanoplasmonic Array
利用高通量 OCEANA 扩大早期癌症检测 - 使用纳米等离子体阵列进行卵巢癌外泌体分析
基本信息
- 批准号:10762488
- 负责人:
- 金额:$ 87.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-19 至 2028-08-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAddressAdoptionAscitesAutomationBenignBiological AssayBiological MarkersBloodBlood TestsBlood specimenCA-125 AntigenCancer ModelCancer PatientCellsChromatographyCirculationClinicalClinical ResearchComplementDiagnosticDiameterDiseaseEarly DiagnosisEpithelial ovarian cancerExcisionGeneral HospitalsGenetic RiskGerm-Line MutationGoalsGynecologicHospitalsImageIndustryInterventionLesionLiquid substanceMalignant - descriptorMalignant Female Reproductive System NeoplasmMalignant neoplasm of ovaryMassachusettsMessenger RNAMethodsMolecularMolecular AnalysisMonitorMusNanotechnologyNucleic AcidsOperative Surgical ProceduresOrganoidsOvarianPathogenesisPathologyPatientsPerformancePerinatalPlasmaProteinsQuality ControlResearchResourcesSamplingScreening for Ovarian CancerScreening for cancerSerousSiteStandardizationStatistical Data InterpretationSystemSystems BiologyTechnologyTestingThinkingTimeTranslatingTumor BurdenUnited StatesUpdateValidationWomanadvanced diseaseassay developmentbiobankbiomarker panelcancer biomarkerscancer carecancer diagnosiscancer imagingcancer subtypescirculating biomarkersclinical translationcohortcomparativedesigndiagnostic valueearly detection biomarkersexosomeextracellular vesicleshigh riskhigh risk populationinsightinstrumentliquid biopsyminimal riskminimally invasivemolecular dynamicsmultidisciplinarynanoplasmonicnovelpatient derived xenograft modelperipheral bloodprophylacticprospectiveprotein biomarkersprotein profilingscreeningsuccesstooltumor progressiontumorigenesis
项目摘要
Ovarian cancer (OvCa) remains the most lethal gynecologic cancer in the United States. Early
detection through screening, particularly of high-risk populations, is an appealing strategy for timely
intervention yet conventional efforts have not improved survival. Extracellular vesicles (EVs; 30-200
nm in diameter) are actively released by cells into circulation, carrying diverse molecular cargo.
Capturing this information could provide a real-time window to monitor tumor burden and dynamic
molecular changes and potentially OvCa precursor lesions. We aim to advance our translational EV
assay for early OvCa diagnosis with a focus on its most lethal subtype, high-grade serous ovarian
cancer (HGSOC). We formed a powerful strategic academic-industry alliance between
Massachusetts General Hospital, Brigham and Women's Hospital, and Exosome Diagnostics and
have laid out two primary objectives. Technology refinement. We will implement an automated and
high-throughput platform, OCEANA (Ovarian Cancer Exosomal Analysis with Nanoplasmonic Array).
We will also construct an EV marker panel to enhance the diagnostic power of EV assays. Expanded
clinical validation. We will rigorously evaluate OCEANA and EV biomarkers using patient-derived
organoids and samples across the clinical spectrum (e.g., benign, early, advanced stages) from a
world-class and gynecologic-focused biorepository. We have four Specific Aims to achieve these
objectives. Aim 1. We will develop a disk-based cartridge for fast, automated total EV isolation. The
underlying technology will be our dual-mode chromatography (DMC) which has demonstrated
superior EV extraction from plasma. Aim 2. We will establish an expanded EV-marker panel for
HGSOC detection informed by patient-derived organoids and EVs. Specifically, EV protein and mRNA
results will be combined to make a multi-analyte marker panel. Aim 3. We will analyze EVs from mice
hosting HGSOC patient-derived xenografts to study the relationship between tumor progression and
circulating EVs. Aim 4. We will screen circulating EVs in women with benign or malignant ovarian
conditions, rigorously evaluating OCEANA's clinical performance. Impact. This project will establish
OCEANA as a transformative tool for comprehensive EV analyses. The clinical study will also validate
EVs as a potent circulating biomarker for early detection of HGSOC. Ultimately, we envision
translating the technology as a monitoring tool for cancer care across research and clinical settings.
卵巢癌(OvCa)仍然是美国最致命的妇科癌症。早期
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Cesar M Castro其他文献
Cesar M Castro的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Cesar M Castro', 18)}}的其他基金
Composing CODAs to cervical cancer screening through an integrated CRISPR and fluorescent nucleic acid approach
通过集成 CRISPR 和荧光核酸方法将 CODA 应用于宫颈癌筛查
- 批准号:
10647930 - 财政年份:2023
- 资助金额:
$ 87.76万 - 项目类别:
High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer
膀胱癌免疫疗法的高通量纳米等离子体外泌体测试(NEXT)
- 批准号:
10463778 - 财政年份:2021
- 资助金额:
$ 87.76万 - 项目类别:
High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer
膀胱癌免疫疗法的高通量纳米等离子体外泌体测试(NEXT)
- 批准号:
10686016 - 财政年份:2021
- 资助金额:
$ 87.76万 - 项目类别:
High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer
膀胱癌免疫疗法的高通量纳米等离子体外泌体测试(NEXT)
- 批准号:
10305371 - 财政年份:2021
- 资助金额:
$ 87.76万 - 项目类别:
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant
达纳法伯/哈佛大学癌症中心卵巢癌孢子补助金
- 批准号:
10684196 - 财政年份:2020
- 资助金额:
$ 87.76万 - 项目类别:
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant
达纳法伯/哈佛大学癌症中心卵巢癌孢子补助金
- 批准号:
10469368 - 财政年份:2020
- 资助金额:
$ 87.76万 - 项目类别:
Early Detection through Novel OCEAN Technology - Ovarian Cancer Exosomal Analysis with Nanoplasmonics
通过新型 OCEAN 技术进行早期检测 - 使用纳米等离子体技术进行卵巢癌外泌体分析
- 批准号:
9982238 - 财政年份:2018
- 资助金额:
$ 87.76万 - 项目类别:
Early Detection through Novel OCEAN Technology - Ovarian Cancer Exosomal Analysis with Nanoplasmonics
通过新型 OCEAN 技术进行早期检测 - 使用纳米等离子体技术进行卵巢癌外泌体分析
- 批准号:
10223236 - 财政年份:2018
- 资助金额:
$ 87.76万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 87.76万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 87.76万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 87.76万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 87.76万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 87.76万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 87.76万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 87.76万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 87.76万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 87.76万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 87.76万 - 项目类别:
Research Grant